hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06374654 id: 2023P003272 briefTitle: RCT of Home-based vs Formal Physical Therapy for Treatment of New Onset Non-insertional Achilles Tendinopathy overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-04 date: 2026-04 date: 2024-04-18 date: 2024-04-18 name: Brigham and Women's Hospital class: OTHER briefSummary: The goal of this prospective randomized controlled trial is to compare the effectiveness of a home-based exercise protocol to formal physical therapy in patients who have been diagnosed with Achilles tendinopathy. The null hypothesis is that there will be no difference in the treatment outcomes between patients with Achilles tendinopathy who participate in a home-based program versus patients with Achilles tendinopathy who undergo formal physical therapy. Participants will be randomized to a 12-week home-based or formal physical therapy protocol and asked to complete brief outcomes surveys at their initial visit, and at 6 weeks, 12 weeks, 6 months, and 1 year after their initial visit. conditions: Achilles Tendinopathy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 56 type: ESTIMATED name: Home-based Exercise Protocol name: Formal Physical Therapy measure: Victorian Institute of Sports Assessment self-administered Achilles questionnaire (VISA-A) measure: PROMIS Pain Interference (4a) measure: PROMIS Pain Intensity (3a) measure: PROMIS Depression (4a) measure: Patient Acceptable Symptom State Questionnaire sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Brigham and Women's Hospital city: Boston state: Massachusetts zip: 02130 country: United States lat: 42.35843 lon: -71.05977 hasResults: False
nctId: NCT06374641 id: 5514255 briefTitle: The Effects of a Novel Mitochondrial Substrate Supplement on Exercise Performance and Cognitive Function acronym: MCh1 overallStatus: RECRUITING date: 2024-03-26 date: 2025-04 date: 2025-08 date: 2024-04-18 date: 2024-04-18 name: University of Exeter class: OTHER name: Mitocholine Ltd name: Innovate UK briefSummary: The goal of this clinical trial is to compare the effects of taking a new supplement for 16 days on cognitive function and exercise performance, compared to a placebo (a supplement that looks and tastes the same, but doesn't have the same ingredients) in 40 healthy individuals - 20 young individuals (aged 18-30) and 20 older individuals (aged 50-65).
After 28 (or 46 for pre-menopausal females) days to make sure the supplement has left the body fully, participants will consume the opposite supplement and repeat the tests. conditions: Exercise Performance conditions: Cognitive Function studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Trials will be randomised and counterbalanced to remove any trial-order effect. primaryPurpose: BASIC_SCIENCE masking: TRIPLE maskingDescription: Partners Innovate UK and Mitocholine Ltd will also be masked. Masking will be performed by an individual outside of the research group. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: Mitochondrial Substrate Supplement name: Placebo Supplement measure: Exercise Capacity measure: VO2 kinetic response to exercise measure: Cognitive Function (Stroop test) measure: Cognitive Function (decision reaction test) measure: Grip Strength measure: Capillary Blood Lactate measure: Questionnaire 1 measure: Questionnaire 2 measure: Venous Blood [Betaine] measure: Venous Blood [Choline] measure: Venous blood [S-Adenosyl methionine] measure: Venous blood [glucose]. measure: Venous blood [insulin]. measure: Venous blood [trimethylamine N-oxide]. sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Richards Building St. Lukes Campus University of Exeter status: RECRUITING city: Exeter state: Devon zip: EX2 4TH country: United Kingdom name: Jimmy T Wangdi, PhD role: CONTACT phone: 01392 661000 email: j.Wangdi4@exeter.ac.uk name: Matthew I Black, PhD role: CONTACT email: M.I.Black@exeter.ac.uk lat: 50.7236 lon: -3.52751 hasResults: False
nctId: NCT06374628 id: 0001 briefTitle: Pre-pectoral Tissue Expander and Acellular Dermal Matrix for a Two-stage Muscle Sparing Breast Reconstruction overallStatus: RECRUITING date: 2019-06-01 date: 2024-04-01 date: 2024-12-31 date: 2024-04-18 date: 2024-04-18 name: Rossella Elia, MD PhD class: OTHER briefSummary: The aim of the research is to evaluate clinical outcomes of a two stage muscle sparing prepectoral breast reconstruction using tissue expander (TE) entirely covered by an ADM. The authors aim to report surgical indications, technical tips, clinical and histological outcomes with the final objective of delineate a decision-making algorithm for immediate prosthetic breast reconstruction. conditions: Breast Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 44 type: ESTIMATED name: breast reconstruction measure: Patient satisfaction measure: Pain Evaluation measure: Complication rate sex: FEMALE stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: AOU Policlinico status: RECRUITING city: Bari state: BA country: Italy name: Rossella Elia role: CONTACT phone: 3409616476 email: rossellaelia4@gmail.com lat: 41.11148 lon: 16.8554 hasResults: False
nctId: NCT06374615 id: 2024-07 briefTitle: Insights Into Tick-Borne Diseases: a Study From an Endemic Area of Northern Italy acronym: TICKTOC overallStatus: RECRUITING date: 2024-03-25 date: 2029-03 date: 2029-03 date: 2024-04-18 date: 2024-04-18 name: IRCCS Sacro Cuore Don Calabria di Negrar class: OTHER briefSummary: This is a monocentric, experimental, non-pharmacological and non-device no profit study.
The study is experimental because all the visits and blood withdrawals foreseen by the protocol do not fall within the normal clinical practice. conditions: Tick-Borne Diseases studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 384 type: ESTIMATED name: IgG and IgM search for specific Tick-Borne Patogens measure: Number of individuals diagnosed with Tick-Borne Diseases (TBD) over the total number of individuals who were bitten by a tick which carried an identified TBP. measure: Number of identified Tick-Borne Patogenees (TBPs) on the total number of analyzed ticks measure: Number of individuals who developed symptoms and were diagnosed for a TBP infection during the 12 weeks' follow-up period measure: Number of individuals who developed specific antibodies against a TBP after tick bite. measure: List of novel TBPs that were not previously found in the study areas. sex: ALL minimumAge: 8 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Sacro Cuore Don Calabria hospital status: RECRUITING city: Negrar state: Verona zip: 37024 country: Italy name: Andrea Tedesco role: CONTACT email: andrea.tedesco@sacrocuore.it name: Andrea Tedesco role: PRINCIPAL_INVESTIGATOR lat: 45.52918 lon: 10.93899 hasResults: False
nctId: NCT06374602 id: 33 briefTitle: Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer overallStatus: RECRUITING date: 2024-03-25 date: 2026-03-25 date: 2026-06-25 date: 2024-04-18 date: 2024-04-18 name: Saint Petersburg State University, Russia class: OTHER briefSummary: This pilot phase 2 study evaluate the effectiveness and safety of pembrolizumab and lenvatinib in patients with anaplastic thyroid cancer. Patients with anaplastic thyroid cancer who are treatment-naive (BRAF-negative) and who were previously treated with chemptherapy or targeted therapy are scheduled to undergo pembrolizumab and lenvatinib and evaluate the outcomes according to the primary and secondary endpoints. conditions: Anaplastic Thyroid Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Pembrolizumab + Lenvatinib measure: Objective response rate measure: Progression-Free Survival measure: Safety and Tolerability assessment (Incidence of Treatment-Emergent Adverse Events) measure: Overall survival measure: The assessment of conversion to resectability sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Saint Petersburg State University Hospital status: RECRUITING city: Saint Petersburg zip: 190020 country: Russian Federation name: Ernest Dzhelialov role: CONTACT phone: +7(911)134-50-44 email: ernest.dzhelialov@gmail.com lat: 59.93863 lon: 30.31413 hasResults: False
nctId: NCT06374589 id: 202303123 briefTitle: Closed-Loop O2 Use During High Flow Oxygen Treatment Of Critical Care Adult Patients (CLOUDHFOT) acronym: CLOUDHFOT overallStatus: ACTIVE_NOT_RECRUITING date: 2024-03-21 date: 2024-08-30 date: 2024-12-30 date: 2024-04-18 date: 2024-04-18 name: Başakşehir Çam & Sakura City Hospital class: OTHER_GOV name: Hamilton Medical AG briefSummary: High flow nasal oxygen therapy (HFNO) is an established modality in the supportive treatment of patients suffering from acute hypoxemic respiratory failure. The high humidified gas flow supports patient's work of breathing, reduces dead space ventilation, and improves functional residual capacity while using an unobtrusive patient's face interface \[Mauri et al, 2017; Möller et al, 2017\].
As hyperoxia is considered not desirable \[Barbateskovic et al, 2019\] during any oxygen therapy, the inspired O2 concentration is usually adapted to a pre-set SpO2 target-range of 92-96% in patients without hypercapnia risk, and of 88-92% if a risk of hypercapnia is present \[O'Driscoll et al, 2017; Beasley et al, 2015\]. In most institutions, the standard of care is to manually adapt the FiO2, although patients frequently have a SpO2 value outside the target range.
A new closed loop oxygen controller designed for HFNO was recently developed (Hamilton Medical, Bonaduz, Switzerland). The clinician sets SpO2 targets, and the software option adjusts FiO2 to keep SpO2 within the target ranges. The software option offers some alarms on low and high SpO2 and high FiO2. Given the capability, on the one hand, to quickly increase FiO2 in patients developing sudden and profound hypoxia, and, on the other hand, of automatically preventing hyperoxia in patients improving their oxygenation, such a system could be particularly useful in patients treated with HFNO.
A short-term (4 hours vs 4 hours) crossover study indicated that this technique improves the time spent within SpO2 pre-defined target for ICU patients receiving high-flow nasal oxygen therapy \[Roca et al, 2022\]. Due to its simplicity, HFNO is increasingly used outside the ICU during transport and in the Emergency Room (ER). This environment poses specific challenges, as patients may deteriorate very quickly and depending on patient's flow, healthcare providers can easily be overwhelmed. We thus propose to evaluate closed loop controlled HFNO in ER patients.
The hypothesis of the study is that closed loop oxygen control increases the time spent within clinically targeted SpO2 ranges and decreases the time spent outside clinical target SpO2 ranges as compared to manual oxygen control in ER patients treated with HFNO. conditions: Acute Hypoxemic Respiratory Failure conditions: Acute Hypercapnic Respiratory Failure conditions: Respiratory Depression conditions: Respiratory Failure studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 50 type: ESTIMATED name: Closed-loop FiO2 controller name: Conventional measure: Percentage of time spent in optimal SpO2 range measure: Percentage of time with SpO2 signal available measure: Percentage of time with SpO2 below target range measure: Percentage of time with SpO2 above target range measure: Percentage of time with SpO2 outside optimal range measure: Percentage of time with with FiO2 below 40% measure: Percentage of time with with FiO2 above 60% measure: Percentage of time with with FiO2 = 100% measure: Mean SpO2/FiO2 measure: Number of events with SpO2 below of target range (duration >10 s) measure: Number of events with SpO2 below of target range (duration >60 s) measure: Number of events with SpO2 below the predefined low SpO2 emergency limit measure: Number of events with SpO2 above the predefined low SpO2 emergency limit measure: Total oxygen use sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Dr.Suat Seren Chest Diseasees Hospital city: Izmir zip: 35230 country: Turkey lat: 38.41273 lon: 27.13838 hasResults: False
nctId: NCT06374576 id: GCIEL briefTitle: Improving eHealth Literacy of Older Adults in Hong Kong overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-06 date: 2024-12 date: 2024-04-18 date: 2024-04-18 name: The University of Hong Kong class: OTHER name: Sino Group name: NG TENG FONG Charitable Foundation briefSummary: This study is an randomized controlled trial (RCT) study to examine the feasibility and effectiveness of a community-based health promotion education intervention for improving the eHealth literacy of older adults conditions: eHealth Literacy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 184 type: ESTIMATED name: Lecture on eHealth literacy name: Digital intervention on eHealth literacy name: Lecture on general health name: Digital intervention on general health measure: eHealth literacy measure: Health Knowledge Learning Intention measure: Online Health Information Seeking measure: Online Health Information Scanning measure: Health-promotion behaviors measure: Health Decision Change sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT facility: The University of Hong Kong city: Hong Kong country: China name: Sophia SC Chan, PhD role: CONTACT phone: 85239176610 email: nssophia@hku.hk name: Sophia SC Chan, PhD role: PRINCIPAL_INVESTIGATOR lat: 22.39407 lon: 114.13737 hasResults: False
nctId: NCT06374563 id: BUC-IACUC-221109-6 briefTitle: Tackling Pressure Ulcer Via Bee Venom Phonophoresis acronym: ulcer overallStatus: COMPLETED date: 2022-11-09 date: 2024-01-01 date: 2024-03-01 date: 2024-04-18 date: 2024-04-18 name: Badr University class: OTHER briefSummary: This study aimed to investigate the efficiency of topical Bee Venom gel versus phonophoresis of Bee Venom gel to accelerate healing of chronic pressure ulcer conditions: Bee Venom conditions: Pressure Ulcers conditions: Phonophoresis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 30 type: ACTUAL name: group 1 received topical Bee venom gel name: Group 2: Phonophoresis of Bee Venom gel measure: wound surface area wound surface area measure: wound volume sex: ALL minimumAge: 40 Years maximumAge: 60 Years stdAges: ADULT facility: Badr University in Cairo city: Cairo zip: 11837 country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06374550 id: 20231026 briefTitle: Jump Start on the Go: Improving Resiliency and the Social-Emotional Development of At-Risk Preschool Children overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-12-01 date: 2025-12-01 date: 2024-04-18 date: 2024-04-18 name: University of Miami class: OTHER briefSummary: The purpose of this study is to test the Jump Start on the Go (JS Go), an app-based program and see how helpful it is at improving resiliency and behavior support within childcare settings. conditions: Mental Health Wellness 1 studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 250 type: ESTIMATED name: Jump Start on the Go name: Jump Start Plus Coronavirus Support measure: Change in classroom practices as measured by Health Environment Rating Scale measure: Change in child behaviors as measured by Devereux Early Childhood Assessments (DECA) measure: Change in child behaviors as measured by Strengths and Difficulties Questionnaire (SDQ) measure: Change in resiliency as measured by Brief Resiliency Coping Scale measure: Change in stress as measured by Childcare Worker Job Stress Index measure: Change in stress as measured by Everyday Stressors Index measure: Change in satisfaction as measured by Teacher Opinion and Satisfaction survey sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Miami city: Miami state: Florida zip: 33136 country: United States name: Ruby Natale, PhD, PsyD role: CONTACT phone: 305-243-4617 email: rnatale@med.miami.edy name: Ruby Natale, PhD, PsyD role: PRINCIPAL_INVESTIGATOR lat: 25.77427 lon: -80.19366 hasResults: False
nctId: NCT06374537 id: 2017-0784 briefTitle: Evaluate the Impact of Targeted Physical Activity on Clinically Debilitated Dialysis Patients. overallStatus: RECRUITING date: 2019-05-22 date: 2026-05-22 date: 2027-05 date: 2024-04-18 date: 2024-04-22 name: University of Illinois at Chicago class: OTHER briefSummary: This research is being done to better understand the impact of the use of a specific physical activity training program (GH Method) in dialysis/kidney disease patients. conditions: Frailty conditions: Pain, Chronic conditions: Dialysis; Complications conditions: Kidney Diseases studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 150 type: ESTIMATED name: Muscle Therapy measure: Rate at which subjects will see changes in their physical abilities. measure: Rate at which exercise will change body composition measure: Rate at which exercise will change handgrip strength. measure: Rate at which subjects enrolled in the exercise intervention will have an overall changed sense of well-being. measure: Rate at which subjects enrolled in the exercise intervention will have an overall changed in their quality of life. measure: Rate at which subjects enrolled in the exercise intervention will have an overall decreased change in depression. measure: Rate at which subjects enrolled in the exercise intervention will have an overall change in pain intensity. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Illinois at Chicago status: RECRUITING city: Chicago state: Illinois zip: 60612 country: United States name: Ilaria Santi role: CONTACT phone: 312-996-9594 email: isanti@uic.edu name: Natalie Isho role: CONTACT phone: 312-996-4708 email: nisho@uic.edu lat: 41.85003 lon: -87.65005 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2023-07-25 uploadDate: 2024-04-15T15:15 filename: Prot_SAP_000.pdf size: 1911663 hasResults: False
nctId: NCT06374524 id: R24-03 briefTitle: Greater Occipital Nerve Block for Spontaneous Intracranial Hypotension overallStatus: NOT_YET_RECRUITING date: 2024-08-01 date: 2026-02-01 date: 2026-06-01 date: 2024-04-18 date: 2024-04-18 name: University Health Network, Toronto class: OTHER briefSummary: SIH is a debilitating neurological disorder caused by a cerebrospinal fluid leak, with an estimated incidence of 5 per 100,000 persons per year, of which mostly women between the ages of 35 years and 55 years (1). The typical presentation is moderate-to-severe orthostatic headache and several other possible neurological symptoms, that significantly impact patients' quality of life (2).
Treatment of SIH usually starts with conservative measures, consisting of strict supine bed rest, hydration, caffeine, and simple analgesics (3). The vast majority of patients will require invasive treatments for their CSF leak, such as epidural blood patches, fibrin glue patches, endovascular coiling, and/or surgical repair (4). These specialized treatments are only offered in tertiary care centers and require specialized personnel and resources, which implicates a certain waiting time for the patients before permanent treatment is offered (5). In the meantime, due to the lack of an effective and accessible alternative, patients continue to suffer.
The GONB has been reported as a simple, safe, and effective treatment to provide short-to-intermediate term relief of migraine (6), cervicogenic headache, cluster headache (7), occipital neuralgia, and more recently, post-dural puncture headaches (PDPH) (8). As the pathophysiology of intracranial hypotension caused by SIH or PDPH is very similar (9), it is stipulated that the effect of GONB will be similar for SIH patients. However, to date, no studies exploring the efficacy of GONB for SIH have been performed.
We propose to do a prospective observational study to explore the outcome of GONB for SIH. GONB can serve as a bridge therapy to control the debilitating headache of SIH while patients are awaiting permanent SIH treatment. Moreover, GONB can be performed by physicians of different specialties including neurology, which makes it an accessible treatment for all patients. Lastly, by offering better symptom control, this intervention could potentially restore patients' ability to work and reduce healthcare costs. conditions: Spontaneous Intracranial Hypotension studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 34 type: ESTIMATED name: greater occipital nerve block measure: Change in headache intensity sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06374511 id: NFEC-2023-546 briefTitle: Prospective Cohort Study of Complications and Outcomes in Cirrhosis overallStatus: RECRUITING date: 2024-01-01 date: 2024-04-04 date: 2025-12-31 date: 2024-04-18 date: 2024-04-18 name: Nanfang Hospital, Southern Medical University class: OTHER briefSummary: This is a multi-center, nested cohort study intended to investigate the prevalence, risk factors, and outcomes of complications in patients with acutely decompensated cirrhosis, especially focused on Cytomegalovirus (CMV) reactivation, bacterial infections, hepatic encephalopathy, and Hepatorenal syndrome. Patients diagnosed with acutely decompensated cirrhosis were enrolled. Upon enrollment, detailed baseline data were collected and samples were harvested. Complications were assessed during hospitalization. Post-discharge follow-up was conducted through telephonic interviews at Day 30 and Day 90. conditions: Decompensated Cirrhosis conditions: CMV Reactivation conditions: Overt Hepatic Encephalopathy studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 660 type: ESTIMATED name: Test for CMV reactivation measure: Incidence of CMV reactivation measure: Incidence of hepatic encephalopathy measure: Response to anti-CMV therapy measure: Response to treatment for hepatic encephalopathy (HE) measure: Survival sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University status: RECRUITING city: Guangzhou state: Guangdong zip: 510515 country: China name: Jinjun Chen, PHD role: CONTACT phone: 86-18588531001 email: chjj@smu.edu.cn lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06374498 id: 2023P003247 briefTitle: Study to Determine the Clinical Significance of Intravascular OCT-NIRAF overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2026-04-30 date: 2027-04-30 date: 2024-04-18 date: 2024-04-18 name: Massachusetts General Hospital class: OTHER briefSummary: Patients undergoing coronary angiography for stable or acute coronary disease presentations and eligible for percutaneous coronary intervention (PCI) will be imaged with OCT-NIRAF at baseline and with CCTA 12 months apart to demonstrate that: